Dr. Mamdani on Evaluating the Immunogenicity of STK11/TP53 Co-Mutations in NSCLC
Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.
Dr. Mamdani on the Need for Novel Therapies in Locally Advanced Esophageal/GEJ Adenocarcinoma
Hirva Mamdani, MD, discusses the need to develop novel therapies in locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512